{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:06Z","timestamp":1790649726102,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>TRC105 is an IgG1 endoglin monoclonal antibody that potentiates VEGF inhibitors in preclinical models. We assessed safety, pharmacokinetics, and antitumor activity of TRC105 in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Subjects, Materials, and Methods<\/jats:title>\n                  <jats:p>Heavily pretreated mRCC patients were treated with TRC105 weekly (8 mg\/kg and then 10 mg\/kg) in combination with axitinib (initially at 5 mg b.i.d. and then escalated per patient tolerance to a maximum of 10 mg b.i.d.) until disease progression or unacceptable toxicity using a standard 3 + 3 phase I design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighteen patients (median number of prior therapies = 3) were treated. TRC105 dose escalation proceeded to 10 mg\/kg weekly without dose-limiting toxicity. Adverse event characteristics of each drug were not increased in frequency or severity when the two drugs were administered concurrently. TRC105 and axitinib demonstrated preliminary evidence of activity, including partial responses (PR) by RECIST in 29% of patients, and median progression-free survival (11.3 months). None of the patients with PR had PR to prior first-line treatment. Lower baseline levels of osteopontin and higher baseline levels of TGF-\u03b2 receptor 3 correlated with overall response rate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TRC105 at 8 and 10 mg\/kg weekly was well tolerated in combination with axitinib, with encouraging evidence of activity in patients with mRCC. A multicenter, randomized phase II trial of TRC105 and axitinib has recently completed enrollment (NCT01806064).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>TRC105 is a monoclonal antibody to endoglin (CD105), a receptor densely expressed on proliferating endothelial cells and also on renal cancer stem cells that is implicated as a mediator of resistance to inhibitors of the VEGF pathway. In this Phase I trial, TRC105 combined safely with axitinib at the recommended single agent doses of each drug in patients with renal cell carcinoma. The combination demonstrated durable activity in a VEGF inhibitor-refractory population and modulated several angiogenic biomarkers. A randomized Phase II trial testing TRC105 in combination with axitinib in clear cell renal cell carcinoma has completed accrual.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0299","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T15:07:00Z","timestamp":1536246420000},"page":"202-210","source":"Crossref","is-referenced-by-count":28,"title":["An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma"],"prefix":"10.1093","volume":"24","author":[{"given":"Toni K.","family":"Choueiri","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dror","family":"Michaelson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Posadas","sequence":"additional","affiliation":[{"name":"Cedars Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[{"name":"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Nixon","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Yuan","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben K.","family":"Seon","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghara","family":"Walsh","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj A.","family":"Jivani","sequence":"additional","affiliation":[{"name":"TRACON Pharmaceuticals, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonne J.","family":"Adams","sequence":"additional","affiliation":[{"name":"TRACON Pharmaceuticals, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"Theuer","sequence":"additional","affiliation":[{"name":"TRACON Pharmaceuticals, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"2021122506315273900_onco12689-bib-0001","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis","volume":"146","author":"Potente","year":"2011","journal-title":"Cell"},{"key":"2021122506315273900_onco12689-bib-0002","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122506315273900_onco12689-bib-0003","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"2021122506315273900_onco12689-bib-0004","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/157488411797189424","article-title":"VEGF inhibitors in renal cell carcinoma: Current therapies and future perspectives","volume":"6","author":"Choueiri","year":"2011","journal-title":"Curr Clin Pharmacol"},{"key":"2021122506315273900_onco12689-bib-0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov"},{"key":"2021122506315273900_onco12689-bib-0006","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1084\/jem.20120662","article-title":"Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination","volume":"210","author":"Anderberg","year":"2013","journal-title":"J Exp Med"},{"key":"2021122506315273900_onco12689-bib-0007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/156720111793663570","article-title":"Endoglin-targeted cancer therapy","volume":"8","author":"Seon","year":"2011","journal-title":"Curr Drug Deliv"},{"key":"2021122506315273900_onco12689-bib-0008","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11912-013-0365-x","article-title":"Endoglin for targeted cancer treatment","volume":"16","author":"Rosen","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"2021122506315273900_onco12689-bib-0009","doi-asserted-by":"crossref","first-page":"43799","DOI":"10.1074\/jbc.M207160200","article-title":"Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways","volume":"277","author":"Sanchez-Elsner","year":"2002","journal-title":"J Biol Chem"},{"key":"2021122506315273900_onco12689-bib-0010","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.284.5419.1534","article-title":"Defective angiogenesis in mice lacking endoglin","volume":"284","author":"Li","year":"1999","journal-title":"Science"},{"key":"2021122506315273900_onco12689-bib-0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1158\/1055-9965.EPI-13-0665","article-title":"Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia","volume":"23","author":"Duarte","year":"2014","journal-title":"Cancer Epi Bio Prev"},{"key":"2021122506315273900_onco12689-bib-0012","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1096\/fj.02-0634rev","article-title":"CD105 is important for angiogenesis: evidence and potential applications","volume":"17","author":"Duff","year":"2003","journal-title":"FASEB J"},{"key":"2021122506315273900_onco12689-bib-0013","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-07-4478","article-title":"Endoglin (CD105): A marker of tumor vasculature and potential target for therapy","volume":"14","author":"Dallas","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122506315273900_onco12689-bib-0014","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1096\/fj.08-102590","article-title":"Identification of a tumor-initiating stem cell population in human renal carcinomas","volume":"22","author":"Bussolati","year":"2008","journal-title":"FASEB J"},{"key":"2021122506315273900_onco12689-bib-0015","doi-asserted-by":"crossref","first-page":"e50920","DOI":"10.1371\/journal.pone.0050920","article-title":"Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies","volume":"7","author":"Nolan-Stevaux","year":"2012","journal-title":"PLoS One"},{"key":"2021122506315273900_onco12689-bib-0016","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-12-0098","article-title":"A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer","volume":"18","author":"Rosen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122506315273900_onco12689-bib-0017","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cam4.71","article-title":"Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab","volume":"2","author":"Liu","year":"2013","journal-title":"Cancer Med"},{"key":"2021122506315273900_onco12689-bib-0018","first-page":"881","article-title":"New guidelines to evaluate the response to treatment in solid tumors [in French]","volume":"87","author":"Duffaud","year":"2000","journal-title":"Bull Cancer"},{"key":"2021122506315273900_onco12689-bib-0019","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clinical Oncol"},{"key":"2021122506315273900_onco12689-bib-0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2021122506315273900_onco12689-bib-0021","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122506315273900_onco12689-bib-0022","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1002\/cncr.30942","article-title":"Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer","volume":"123","author":"Dorff","year":"2017","journal-title":"Cancer"},{"key":"2021122506315273900_onco12689-bib-0023","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1158\/1078-0432.CCR-16-2395","article-title":"The DART study: Results from the dose-escalation and expansion cohorts evaluating the combination of dalantercept plus axitinib in advanced renal cell carcinoma","volume":"23","author":"Voss","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122506315273900_onco12689-bib-0024","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-16-3171","article-title":"Phase I and preliminary phase II study of TRC105 in combination with sorafenib in hepatocellular carcinoma","volume":"23","author":"Duffy","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/202\/41916964\/oncolo_24_2_202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/202\/41916964\/oncolo_24_2_202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:32:06Z","timestamp":1640413926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/2\/202\/6439082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,9,6]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0299","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,1]]},"published":{"date-parts":[[2018,9,6]]}}}